10.1038/s41523-022-00467-1 - Safety analyses from the phase 3 ASCE...

This document has been corrected

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

10.1038/s41523-022-00467-1

Published Online: 2022-08-29

Journal: npj Breast Cancer•Publisher: Springer Science and Business Media LLC

Authors: Aditya Bardia•David M. Goldenberg•Delphine Loirat•Hope S. Rugo•Javier Cortés•Joyce O’Shaughnessy•Kevin Kalinsky•Kevin Punie•Lisa A. Carey•Loretta M. Itri•Luca Gianni•Martin Olivo•Martine J. Piccart•Quan Hong•Sara A. Hurvitz•Sara M. Tolaney•Sibylle Loibl•Véronique Diéras

This document has been corrected

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

10.1038/s41523-022-00467-1

Published Online: 2022-08-29

Journal: npj Breast Cancer

NOW

2024-06-06•Correction

Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

10.1038/s41523-024-00650-6

* information provided by CrossRef

2024-06-06•Correction

10.1038/s41523-024-00650-6

* information provided by CrossRef

2022-08-29•Published

2024-06-06•Correction

Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

10.1038/s41523-024-00650-6

* information provided by CrossRef

This document has been corrected

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

10.1038/s41523-022-00467-1

Published Online: 2022-08-29

Journal: npj Breast Cancer•Publisher: Springer Science and Business Media LLC